Effects of Raman Labeling Compounds on the Stability and Surface-Enhanced Raman Spectroscopy Performance of Ag Nanoparticle-Embedded Silica Nanoparticles as Tagging MaterialsArticle Published on 2024-05-262024-09-05 Journal: Biosensors [Category] update2024, [키워드] Ag NPs Period pH Raman labeling compound SERS tags stability Surface-enhanced Raman spectroscopy temperature [DOI] 10.3390/bios14060272 PMC 바로가기 [Article Type] Article
Concordance of SARS-CoV-2 Antibody Results during a Period of Low PrevalenceArticle Published on 2022-10-262022-11-15 Journal: mSphere [Category] COVID19(2023년), SARS, 진단, [키워드] 95% confidence interval Abbott acute respiratory syndrome Analysis anti-SARS-CoV-2 anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG Antigen antigens Architect assays CDC collected combinations Concentration Concordance contributed coronavirus coronavirus disease COVID-19 Elecsy ELISA enzyme-linked immunosorbent evaluate False positivity first test Frequency IgG IgG antibodies immunoassay immunoassays Immunoglobulin individual investigated low prevalence nucleocapsid nucleocapsid protein pandemic participant Participants performed Period positive positive result Prevalence produced proportion quantified Research Result Roche SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 IgG antibody sequential test sera serological test seropositive specimen Spike protein subset Support target tested the SARS-CoV-2 The United States Vaccine vaccine availability [DOI] 10.1128/msphere.00257-22 PMC 바로가기
Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States – IVY Network, 18 States, December 26, 2021-August 31, 2022Article Published on 2022-10-212022-11-16 Journal: Morbidity and Mortality Weekly Report [Category] COVID19(2023년), SARS, 변종, [키워드] accounted Against B.1.1.529 booster dose category COVID-19 vaccine dose Effectiveness eligible adult estimate expected Hospitalization Immunity immunocompetent adult immunogenic include Infection Interpretation Lineage lineages majority monovalent mRNA mRNA component mRNA COVID-19 vaccine mRNA vaccine network omicron overlapped Period predominant Prevent protection receive reduce replaced SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 strain second dose the United State vaccination Vaccine Vaccine-induced immunity variant waned [DOI] 10.15585/mmwr.mm7142a3 PMC 바로가기
A Comparative Study of Asymptomatic Malaria in a Forest Rural and Depleted Forest Urban Setting during a Low Malaria Transmission and COVID-19 Pandemic Period말라리아 전파율이 낮고 코로나19 팬데믹 기간 동안 농촌 산림과 산림이 고갈된 도시 환경에서 무증상 말라리아에 대한 비교 연구Article Published on 2022-10-152022-11-15 Journal: BioMed Research International [Category] 말라리아, 치료기술, 치료제, [키워드] 95% CI activity Antigen Asymptomatic characteristic Community Comparative COVID-19 COVID-19 pandemic Depleted determine ecological enrolled expected forest Intervention logistic regression models malaria morbidity and mortality multivariate model Odds ratio participant Participants Period Plasmodium falciparum positive predictor Prevalence questionnaire Randomly Risk factors setting socio-demographic statistically significant Transmission urban was performed zone [DOI] 10.1155/2022/2545830 PMC 바로가기
COVID-19 Symptoms and Duration of Rapid Antigen Test Positivity at a Community Testing and Surveillance Site During Pre-Delta, Delta, and Omicron BA.1 PeriodsArticle Published on 2022-10-032022-11-16 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 변종, [키워드] addition age Antigen Asymptomatic booster children clinical symptom Community conducted cough COVID-19 COVID-19 symptom COVID-19 testing cross-sectional Delta Duration Evolution Fever first positive Fisher Health Isolation Latinx less loss of taste median myalgia negative test omicron outcome participant Participants Patient Period population immunity positive positive result positive test result Practitioner proportion public health Rapid remained repeated reported reported symptoms San Francisco SARS-COV-2 infection seeking Site sore throat Symptom symptom onset symptomatic symptomatic participant Symptoms Test tested Testing upper respiratory tract vaccination Vaccine variant Viral variants were used with COVID-19 worsening χ2 test [DOI] 10.1001/jamanetworkopen.2022.35844 PMC 바로가기
Increased Mortality Among Persons With Symptomatic Coronavirus Disease 2019 (COVID-19) During the Period of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.617.2 (Delta Variant) Predominance: Alaska, November 2020-October 2021Article Published on 2022-10-032022-11-16 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 변종, [키워드] Alaska B.1.617.2 B.1.617.2 (Delta) coronavirus 2 coronavirus disease COVID-19 death Delta delta variant higher odd Increased Mortality mortality risk Period Person predominant respiratory risk SARS-CoV-2 symptomatic vaccination virulence [DOI] 10.1093/cid/ciac530 PMC 바로가기
Mortality Risk Among Patients Hospitalized Primarily for COVID-19 During the Omicron and Delta Variant Pandemic Periods – United States, April 2020-June 2022Article Published on 2022-09-162022-11-16 Journal: Morbidity and Mortality Weekly Report [Category] SARS, 변종, [키워드] adjusted age calculated cause CDC Clinical characteristics COVID-19 COVID-19 hospitalization database deaths Delta early treatment Ethnic groups females Health authority hospital hospitalized COVID-19 patient hospitalized patients In-hospital death in-hospital mortality increase indicated lower mortality male medical condition Medical conditions Mortality mortality risk nonpharmaceutical intervention occurred omicron pandemic Patient patients hospitalized Period proportion public health Racial reported risk United States variant variant of SARS-CoV-2 virus [DOI] 10.15585/mmwr.mm7137a4 PMC 바로가기
Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United StatesArticle Published on 2022-09-012022-11-16 Journal: JAMA Network Open [Category] SARS, 변종, 유전자 메커니즘, [키워드] 95% CI adjusted odds ratio Against age black booster dose calculated Care case-control study conducted COVID-19 COVID-19 vaccination COVID-19 vaccine Delta delta variant dose Effectiveness eligible estimate Estimated estimation evaluate high risk Hispanic hospital Hospitalization hospitalizations IQR laboratory-confirmed molecular mRNA mRNA vaccination mRNA vaccine omicron outcome Patient Period positive Pregnancy pregnant protection SARS-CoV-2 severe COVID-19 the median the United State variant waned were excluded [DOI] 10.1001/jamanetworkopen.2022.33273 PMC 바로가기
High Sensitivity and NPV for BinaxNOW Rapid Antigen Test in Children at a Mass Testing Site during Prevalent Delta Variant PeriodArticle Published on 2022-08-312022-11-16 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI Abbott Antigen Asymptomatic children COVID-19 COVID-19 test Delta develop dominant Efficacy evaluated increasingly mass nare Negative predictive value NPV participant Participants PCR pediatric pediatric rapid antigen testing. performed Period positive Positive predictive value PPV predominant presenting Rapid reported RT-PCR Safe SARS-CoV-2 sensitivity Site specificity swabs symptom status symptomatic and asymptomatic symptomatic participants Test tested Testing variant Viral load [DOI] 10.1128/spectrum.00236-22 PMC 바로가기
Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Updated Analysis Involving 22,607 Blood Donors Covering the Period October 2021 to April 2022Article Published on 2022-08-252022-11-15 Journal: Viruses [Category] SARS, 진단, 치료기술, [키워드] age anti-SARS-CoV-2 anti-SARS-CoV-2 antibody anti-Spike IgG anti-spike IgG antibodies antibody average Blood Blood donors category Covering detectable estimate female geometric IgG IgG antibody IgG level incidence individual infected with SARS-CoV-2 Involving median P -value participant percentage Period proportion public health quantified remained required SARS-CoV-2 seropositive participant seropositive participants Seroprevalence undetectable vaccinated individual [DOI] 10.3390/v14091877 PMC 바로가기